Is MGTX's Q1 2025 EPS forecast achievable?

**MeiraGTx Holdings plc (MGTX) is not expected to achieve a positive EPS in Q1 2025.** Here's a detailed analysis: 1. **Current Financial Outlook**: The estimated EPS for MGTX in Q1 2025 is -$0.38. This indicates that the company is expected to report a loss during this quarter. 2. **Recent Performance and Analyst Expectations**: - MGTX has been closely monitored by analysts, with expectations of breakeven in the near future. However, the projected EPS in Q1 2025 is negative, suggesting that the company is still expected to be in the loss-making phase. - Piper Sandler, a prominent analyst firm, has maintained an "Overweight" rating on MGTX with a steady price target of $26.00, indicating confidence in the company's potential. Despite this positive outlook, the Q1 2025 EPS forecast does not reflect profitability. 3. **Market Conditions and Company Strategy**: MGTX has been actively managing its financials and strategic partnerships. The company's joint venture with Hologen is expected to enhance manufacturing capabilities and extend its cash runway. While these developments are positive, they may not immediately impact the EPS in Q1 2025. 4. **Historical Performance and Industry Trends**: MGTX has shown significant revenue growth, with a 137.7% year-over-year increase in revenue in the latest fiscal year. However, this growth has not yet translated to positive net income, as evidenced by the EPS forecast for Q1 2025. In conclusion, based on the current EPS forecast and the company's recent performance, it is unlikely that MGTX will achieve profitability in Q1 2025. The projected negative EPS is a reflection of the company's ongoing investment phase and the challenges inherent in the biotechnology sector. While MGTX has several strategic initiatives that could positively impact its financials in the future, these are not expected to materialize in time for the Q1 2025 earnings report.